HPSE and liver cancer: Twoanti-heparanase antibodies (multiple antigenic peptides MAP1 and MAP2) caneffectively inhibit the heparanase activity of HCCLM6 liver cancer cells, therebyinfluencing their invasive capacity (Yang etal., 2009).